Menu

Another Andrew Wakefield Movie in the Works

This one will be largely based on the discredited anti-vaccine researcher’s 2010 book.

May 4, 2016
Bob Grant

YOUTUBE, THE WELLNESS WAY CLINICSIt looks like notorious anti-vaccine researcher Andrew Wakefield will make it onto the silver screen yet again. A month ago, the documentary he co-directed, Vaxxed, premiered in New York City. Now, a Hollywood screenwriter—with cowriting credits on blockbusters including Shrek and Pirates of the Caribbean—intends to write a film adaptation of Wakefield’s 2010 book Callous Disregard: Autism and Vaccines—The Truth Behind a Tragedy.

By all appearances, the new film will be a sympathetic look at the life and work of Wakefield, whose claims that measles, mumps, and rubella (MMR) vaccines cause autism have been thoroughly debunked by reams of scientific research. Wakefield himself was repudiated by publishers and the U.K.’s General Medical Council for violating ethical standards. Similarly, the claims Wakefield made in Callous Disregard have been disproven. “[The book] is just terrible,” Joel Harrison, a retired epidemiologist who wrote a point-by-point takedown of Wakefield’s book in a 2013 The Open Vaccine Journal article, told STAT News. “If he handed it in as a term paper as an undergraduate, I wouldn’t pass him.”

Terry Rossio, the screenwriter taking on the new Wakefield movie project, has indicated that the film will highlight the work and life of the controversial researcher. “Dr. Wakefield is clearly a polarizing figure, reviled by the general public yet also revered by many,” he told Variety. “The details and drama surrounding his life are even more remarkable than generally known.”

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN Ltd are pleased to announce the commercial licensing of CRISPR-Cas9 gene-editing technology from Broad Institute of MIT and Harvard in the USA, to develop human cell disease models to support preclinical metabolic disease therapeutic programmes.

Thermo Fisher Scientific: Freezers for Biological Samples

Thermo Fisher Scientific: Freezers for Biological Samples

Fluctuations in temperature can reduce the efficacy, decompose, or shorten the shelf life of biologics. Therefore, it is important to store biologics at the right temperature using standardized protocols.